Robbins llp urges regn stockholders with large losses to contact the firm for information about the class action against regeneron pharmaceuticals, inc

San diego, jan. 17, 2025 (globe newswire) -- robbins llp reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired regeneron pharmaceuticals, inc. (nasdaq: regn) securities between november 2, 2023 and october 30, 2024. regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.
REGN Ratings Summary
REGN Quant Ranking